Drug Information

Drug General Information
Drug ID
D0B4CD
Former ID
DIB008395
Drug Name
GSK-2018682
Synonyms
PPI-4621; PPI-4667; PPI-4939; PPI-4955; PPI-4667-P; PPI-5955-P; S1P1 receptor agonists (immune disorder), GlaxoSmithKline
Indication Immune disorder [ICD10:D80-D89] Phase 1 [523536]
Company
Praecis Pharmaceuticals Inc
Canonical SMILES
c1(c2ccc(OCc3ccc(c4ccccc4)cc3)c(c2)C(F)(F)F)[nH]c(nc1)[<br />C@](CO)(N)C
Target and Pathway
Target(s) Sphingosine 1-phosphate receptor 1 Target Info Agonist [532456]
KEGG Pathway FoxO signaling pathway
Sphingolipid signaling pathway
Neuroactive ligand-receptor interaction
NetPath Pathway IL4 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
IL2 Signaling Pathway
Pathway Interaction Database Fc-epsilon receptor I signaling in mast cells
S1P3 pathway
S1P1 pathway
Sphingosine 1-phosphate (S1P) pathway
PDGFR-beta signaling pathway
Reactome G alpha (i) signalling events
Lysosphingolipid and LPA receptors
WikiPathways Signal Transduction of S1P Receptor
Small Ligand GPCRs
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 523536ClinicalTrials.gov (NCT01387217) GSK2018682 FTIH in Healthy Volunteers. U.S. National Institutes of Health.
Ref 532456Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.